This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:
NCT01756898
First received: November 9, 2012
Last updated: October 19, 2015
Last verified: October 2015
  Purpose
The purpose of this research study is to gather scientific information about the effectiveness of the study drug, ASB17061 capsules, when compared to placebo in adult subjects with atopic dermatitis.

Condition Intervention Phase
Atopic Dermatitis Drug: ASB17061 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Resource links provided by NLM:


Further study details as provided by Daiichi Sankyo Inc.:

Primary Outcome Measures:
  • Investigator's Global Assessment (IGA) [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • Eczema Area and Severity Index Score (EASI) [ Time Frame: 8 weeks ]
  • The Percentage of Body Surface Area (BSA) Involved [ Time Frame: 8 weeks ]
  • Pruritus Score [ Time Frame: 8 weeks ]
  • Insomnia Score [ Time Frame: 8 weeks ]
  • Number of Patients with Abnormal Findings in Electrocardiograms, Serum Biomarkers, Clinical Laboratory Test, and Vital Signs [ Time Frame: 8 weeks ]
  • Population Pharmacokinetics: AUC and Cavg [ Time Frame: 4 weeks ]
  • Number of Patients with Adverse Events [ Time Frame: 8 weeks ]

Enrollment: 370
Study Start Date: December 2012
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low dose ASB17061
Oral administration of low dose ASB17061 taken once daily for 28 consecutive days.
Drug: ASB17061
Oral administration of ASB17061 taken once daily for 28 consecutive days.
Experimental: Middle dose ASB17061
Oral administration of middle dose ASB17061 taken once daily for 28 consecutive days.
Drug: ASB17061
Oral administration of ASB17061 taken once daily for 28 consecutive days.
Experimental: High dose ASB17061
Oral administration of high dose ASB17061 taken once daily for 28 consecutive days.
Drug: ASB17061
Oral administration of ASB17061 taken once daily for 28 consecutive days.
Placebo Comparator: Placebo
Oral administration of placebo taken once daily for 28 consecutive days.
Drug: Placebo
Oral administration of placebo taken once daily for 28 consecutive days.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult subjects ages 18 to 65 years
  • A diagnosis of atopic dermatitis (AD)
  • An IGA score of 2 or higher and AD affecting at least 5% of total Body Surface Area (BSA)
  • Other than active AD, in good health with no medical condition that may jeopardize the safety of the subject or impact the validity of the study results
  • Subjects must be practicing acceptable birth control methods

Exclusion Criteria:

  • Taking systemic immunosuppressive therapy within 3 months prior to screening or systemic (cortico) steroid therapy within 4 weeks prior to screening
  • Use of phototherapy or tanning beds within 6 weeks of screening
  • Presence of a clinically significant disorder involving gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition, which will jeopardize the safety of the subject or impact the validity of the study results
  • Female subjects who are pregnant or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01756898

  Show 40 Study Locations
Sponsors and Collaborators
Daiichi Sankyo Inc.
Investigators
Study Director: Ger Rikken, MD Asubio Pharmaceuticals, Inc.
  More Information

Responsible Party: Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier: NCT01756898     History of Changes
Other Study ID Numbers: ASBI 704
Study First Received: November 9, 2012
Last Updated: October 19, 2015

Keywords provided by Daiichi Sankyo Inc.:
Atopic Dermatitis
eczema

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on June 23, 2017